CD34+ cell count/kg bw in the graft has been shown to be predictive for survival in different haematological diseases following PB-HSCT (CD34+ > 4.5 × 106/kg bw only 18 CML patients) and BM-HSCT (CD34+ > 3 × 106/kg bw; 55 patients with CML, of which 11 accelerated phase and 2 in BC) [15, 16]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.